Skip to main content

Day: March 9, 2024

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Written by Customer Service on . Posted in Public Companies.

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific patternSAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis. The Arcutis sponsored research from The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai was presented in a scientific session at the American Academy of Dermatology (AAD) annual meeting (San Diego, CA, March 8 – 12) and answers key questions...

Continue reading

Linde plc to Join the Nasdaq-100 Index® Beginning March 18, 2024

Written by Customer Service on . Posted in Public Companies.

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Linde plc (Nasdaq: LIN), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX®), the Nasdaq-100 Equal Weighted™ Index (Nasdaq: NDXE™), the Nasdaq-100 Ex-Tech Sector™ Index (Nasdaq: NDXX™), and the Nasdaq-100 ESG™ Index (Nasdaq: NDXESG™) prior to market open on Monday, March 18, 2024. Linde plc will replace Splunk Inc. (Nasdaq: SPLK) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. Splunk will also be removed from the Nasdaq-100 ESG™ Index (Nasdaq: NDXESG™) and the Nasdaq-100 Tech Sector™ Index (Nasdaq: NDXT™) on the same date. For more information about the company, go to https://www.linde.com/. About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.